Zaqubo Shows Symptom Improvement in 5,514-Patient Real-World Study After Just 4 Weeks

GERD Patients Show Improvement in Heartburn and Acid Regurgitation Symptoms
After 4 Weeks of Treatment

92% Report High Satisfaction with Therapy

The results of a large-scale real-world data (RWD) study on the gastroesophageal reflux disease (GERD) treatment Zaqubo (ingredient name: Zastaflazan) developed by Onconic Therapeutics have been published in an international academic journal. It was confirmed that patients who switched to Zaqubo after previously using proton pump inhibitors (PPIs) and P-CAB treatments also experienced symptom improvement.

On September 1, Onconic Therapeutics announced that a paper presenting the large-scale real-world data study results for Zaqubo Tab 20mg has been published in the international gastroenterology journal 'JNM.'

Graph showing the change in Gastroesophageal Reflux Disease (GERD) scores for Jastaflajan. Oncogenic Therapeutics

This study was a multicenter, prospective, observational study conducted at 382 primary care centers in Korea from October 2024 to April 2025. A total of 5,514 adult GERD patients were administered Zaqubo Tab 20mg once daily for four weeks, and assessments were conducted for symptom improvement, patient satisfaction, medication adherence, and safety. The efficacy evaluation included 5,499 participants.

Symptom assessment was carried out using the reflux disease questionnaire (RDQ), a patient-reported tool that measures the frequency and severity of symptoms such as heartburn and acid regurgitation. The results showed that the primary endpoint, the RDQ GERD score, decreased by 1.63 points, from a baseline mean of 2.07 before Zaqubo administration to 0.44 after four weeks.

In terms of safety, adverse drug reactions were confirmed in 3 patients (0.05%), and all cases were mild. No moderate or severe adverse drug reactions or serious adverse events (SAE) were reported.

Treatment satisfaction was high, with 93.4% for efficacy, 92.7% for ease of administration, and 92.1% for side effect management; in all categories, over 92% of respondents answered "satisfied" or "very satisfied." The average medication adherence reported by 5,496 respondents was 93%.

Symptom improvement was also observed in patients who switched from previous GERD treatments to Zaqubo. For the 4,906 patients without any prior treatment history, the RDQ GERD score decreased by an average of 1.64 points. Among 593 patients who switched to Zaqubo after taking conventional treatments such as H2RA, PPI, or P-CAB, the average decrease was 1.60 points.

This study was presented in May at Digestive Disease Week (DDW 2026) in the United States. The principal investigator, Kim Yongseong, adjunct professor at the Gastrointestinal Disease Research Institute of Wonkwang University College of Medicine, stated, "This study is valuable because the results were obtained from diverse patient groups in real-world primary care settings, beyond the controlled environment of clinical trials." He added, "Consistent symptom improvement was observed not only in patients transitioning from PPIs but also in those who switched from P-CAB agents to Zaqubo."

This content was produced with the assistance of AI translation services.